Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate

Thrombosis Research

Volumn 122, Issue 1, 2008, Pages 109-116

  Fabiana Alberto, María ^a   Giaquinta Romero, Diego ^b   Lazzari, María ^a   Calabrese, Graciela C ^b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Complement system; Dermatan sulfate; Fibrinolysis; Glycosaminoglycans; Heparin cofactor II

Indexed keywords

DERMATAN SULFATE; HEPARIN COFACTOR II;

ANIMAL MODEL; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG BIOAVAILABILITY; DRUG INHIBITION; FIBRINOLYSIS; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; THROMBIN TIME; THROMBOGENESIS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; COMPLEMENT SYSTEM PROTEINS; DERMATAN SULFATE; FIBRINOLYTIC AGENTS; HEMOLYSIS; MALE; MOLECULAR WEIGHT; RATS; RATS, WISTAR; THROMBIN;

EID: 42649109078     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.09.001     Document Type: Article

References (42)

1. Iozzo R. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67 (1998) 609-652
2. Pavao M., Aiello K., Werneck C., Silva L.C.F., Valente A.P., Mulloy B., et al. Highly sulfated dermatan sulfates from ascidians. Structures versus anticoagulant activity of these glycosaminoglycans. J Biol Chem 273 43 (1998) 27848-27857
3. Tollefsen D. Insight into mechanism of action of heparin cofactor II. Thromb Haemost 74 5 (1995) 2162-2169
4. Desnoyers P., Bara L., and Samama M. Dermatan sulfate and the prevention of experimental thrombosis. Pathol Biol 37 6 (1989) 759-767
5. Hennan J.K., Hong T.T., Shergill A.K., Driscoll E.M., Cardin A.D., and Lucchesi B.R. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther 301 (2002) 1151-1156
6. Cofrancesco E., Boschetti C., Leonardi F.G., and Cortellaro M. Dermatan sulphate for treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: a randomised, heparin-controlled pilot study. Thromb Res 7 (1994) 65-75
7. Di Carlo V., Agnelli G., Pradoni P., Coccheri S., Gensini G.F., Gianese F., et al. for the "DOS" (dermatan sulphate in oncology surgery) study group. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. Thromb Haemost 82 (1999) 30-34
8. Bedayan P., Boccalon H., Dupouy D., and Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound inhibition that unfractionated and low molecular weight heparins. Thromb Haemost 71 5 (1994) 576-580
9. Liaw P.C., Becker D.L., Stafford A.L., Fredenburgh J.C., and Weitz J.I. Molecular basis for susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276 24 (2001) 20959-20965
10. Nenci G. Dermatan sulphate as antithrombotic drug. Pathophysiol Haemost Thromb 32 (2002) 604-614
11. Wuillemin W.A., te Velthuis H., Lubbers Y.T., de Ruig C.P., Eldering E., and Hack C.E. Potentiation of C1 inhibitor by glycosaminoglycans dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 159 4 (1997) 1953-1960
12. Calabrese G.C., Alberto M.F., Tubio R., Marani M.M., Fernández de Recondo M.E., Lazzari M., et al. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein. Thromb Res 113 (2004) 243-250
13. Mascellani G., Liverani L., Parma B., Bergonzini G., and Bianchini P. Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor. Thromb Res 84 1 (1996) 21-32
14. 13CNMR studies of reduced disaccharides and tetrasaccharides. Eur J Biochem 268 (2001) 1181-1189
15. Pavao M.S., Mourao P.A., Mulloy B., and Tollefsen D.M. A unique dermatan sulfate-like glycosaminoglycan from ascidian. J Biol Chem 270 52 (1995) 31027-31036
16. Heinzel G., Woloszczak R., and Thoman P. Pharmacokinetic and pharmacodynamic data analysis system. In: Fisher G. (Ed) (1993), Stuttgart
17. 2-glycoprotein I-depleted plasma. Thromb Res 76 2 (1994) 199-210
18. Groeneveld T.W., Oroszlán M., Owens R.T., Faber-Krol M.C., Brakker A.C., Arlaud G.J., et al. Interactions of extracellular matrix proteoglycans decorin and biglycan with C1q collectins. J Immunol 175 (2005) 4715-4723
19. Alban S., Birgit C., and Brunner G. Differentiation between the complement modulating effects of an Arabinogalactan-protein from Echinacea purpurea and heparin. Planta Med 68 (2002) 1118-1124
20. a Edición (1996), Editorial Médica Panamericana, Buenos Aires 386-420
21. Doutremepuich C., Azougagh Oualane F., and Doutremepuich F. New class of heparin derivates with a potent antithrombotic effect and very limited hemorrhagic activity. Thromb Res 83 3 (1996) 217-228
22. Calabrese G.C., Recondo E.F., and Fernandez de Recondo M. Antithrombin and first complement protein recognize the same active heparin fraction. Thromb Res 105 (2002) 537-541
23. Pavao M.S.G., Mourao M.P.A.S., Mulloy B., and Tollefsen D.G. A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity. J Biol Chem 270 52 (1995) 31027-31036
24. Takada Y., Urano T., Takahashi H., Nagai N., and Takada A. Effects of electric footshock and water immersion restraint stresses on fibrinolytic parameters in the plasma rats. Thromb Res 89 (1998) 107-114
25. Halldorsdottir A.M., Zhang L., and Tollefsen D. N-acetylgalactosamina 4,6 O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosa dermatan sulfate. Glycobiol 16 8 (2006) 693-701
26. Agnelli G., Cosmi B., Renga C., Federioci F., Nenci G., Houin G., et al. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion. Thromb Haemost 64 2 (1990) 256-259
27. Du H.Y., Song S.L., Ye H.F., and Cao J.C. The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities. Thromb Res 119 (2007) 377-384
28. Buchanan M.R., Maclean G.A., and Brister S.J. Selective and sustained inhibition of-surface-bound thrombin activity by Intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro. Thromb Haemost 86 (2001) 909-913
29. Colucci M., Pentimone A., Binetti B.M., Cramarossa D.P., and Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost 88 (2002) 282-287
30. Calabrese G.C., Leocata Nieto F., Recondo E.F., and Fernandez de Recondo M. An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement System. Cell Mol Biol 47 17 (2001) 127-131
31. Lucchesi B.R., and Tanhehco E.J. Therapeutic potential of complement inhibitors in myocardial ischaemia. Expert Opin Investig Drugs 9 (2000) 975-991
32. Yu H., Muñoz E.M., Edens R.E., and Linhardt R.J. Kinetic studies on the interaction of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta 1726 2 (2005) 168-176
33. Bazargoni F., Albrektson A., Yahyapour B., and Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int 25 4 (2005) 394-404
34. Girardi G., Redecha P., and Salomon J.E. Heparins prevent antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 11 (2004) 1222-1226
35. Girardi G., Bulla R., Salmon J.E., and Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 43 1-2 (2006) 68-77
36. Hong T.T., White A., and Lucchesi B. Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart. Int Immunopharmacol 5 (2005) 381-391
37. Blom A.M. A cluster of positively charged amino acids in the α-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria. Scand J Clin Lab Invest 60 233 (2000) 37-49
38. Ferreira V.P., Herbert A.P., Hocking H.G., Barlow P.N., and Pangurn N.K. Critical role of C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 177 (2006) 6308-6316
39. Saito A., and Munakata H. Factor H is a dermatan sulfate-binding protein: identification of a dermatan sulfate-mediated protease that cleaves factor H. J Biochem 137 2 (2005) 225-233
40. Mantovani A., Sozzani S., Vecchi A., Introna M., Allavena P., et al. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 78 1 (1997) 406-414
41. Coughlin S. Thrombin signaling and protease-activated receptors. Nature 407 (2000) 258-264
42. He L., Vicente C.P., Westrick R., Eiztman D.T., and Tollefsen D.M. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 109 2 (2002) 213-219